Evidence map›Paper›PMID 35722463›Full record

ArticleBioMed research international2022

Developing a Multimodal Model for Detecting Higher-Grade Prostate Cancer Using Biomarkers and Risk Factors.

Palanivel Velmurugan, Vinayagam Mohanavel, Anupama Shrestha, Subpiramaniyam Sivakumar, Atif Abdulwahab A Oyouni, Osama M Al-Amer, Othman R Alzahrani, Mohammed I Alasseiri, Abdullah Hamadi, Adel Ibrahim Alalawy

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Palanivel VelmuruganCentre for Materials Engineering and Regenerative Medicine, Bharath Institute of Higher Education and Research, Selaiyur, Chennai, Tamil Nadu, India.ORCID https://orcid.org/0000-0001-6506-1953
Vinayagam MohanavelCentre for Materials Engineering and Regenerative Medicine, Bharath Institute of Higher Education and Research, Chennai 600073, Tamil Nadu, India.
Anupama ShresthaDepartment of Plant Protection, Himalayan College of Agricultural Sciences and Technology, Kalanki, Kathmandu, Nepal PO box 44600.ORCID https://orcid.org/0000-0003-4476-1832
Subpiramaniyam SivakumarDepartment of Bioenvironmental Energy, College of Natural Resources and Life Science, Pusan National University, Miryang-Si, Gyeongsangnam-do 50463, Republic of Korea.
Atif Abdulwahab A OyouniDepartment of Biology, Faculty of Sciences, University of Tabuk, Tabuk, Saudi Arabia.ORCID https://orcid.org/0000-0001-8762-4999
Osama M Al-AmerGenome and Biotechnology Unit, Faculty of Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Othman R AlzahraniDepartment of Biology, Faculty of Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Mohammed I AlasseiriDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.ORCID https://orcid.org/0000-0003-0406-1524
Abdullah HamadiDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Adel Ibrahim AlalawyGenome and Biotechnology Unit, Faculty of Sciences, University of Tabuk, Tabuk, Saudi Arabia.
University of Tabuk · SABharath University · INChandigarh University · INNepal Development Research Institute · NPPusan National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A technique to predict crucial clinical prostate cancer (PC) is desperately required to prevent diagnostic errors and overdiagnosis. To create a multimodal model that incorporates long-established messenger RNA (mRNA) indicators and conventional risk variables for identifying individuals with severe PC on prostatic biopsies. Urinary has gathered for mRNA analysis following a DRE and before a prostatic examination in two prospective multimodal investigations. A first group (

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorBiopsyHumansMaleProspective StudiesRisk FactorsRNA, MessengerBiomarkers, TumorProstate-Specific AntigenRNA, Messenger

Identifiers

PMID35722463
PMCPMC9205705
OpenAlexW4281623598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.